COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment of Refractory Angina Pectoris by Shock Wave Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00776568
Recruitment Status : Unknown
Verified October 2008 by Universal Research Group.
Recruitment status was:  Active, not recruiting
First Posted : October 21, 2008
Last Update Posted : October 21, 2008
Information provided by:
Universal Research Group

Brief Summary:
The purpose of this study is to determine that extracorporeal shock wave therapy (ESWT) is safe and effective for the treatment of refractory angina pectoris.

Condition or disease Intervention/treatment Phase
Angina Pectoris Procedure: Extra-corporeal shockwave Drug: Anti-hypertensive drugs Phase 3

Detailed Description:

Patients with advanced CAD frequently have limited symptoms with recurrent angina, angina at low work thresholds, breathlessness, and other debilitating conditions. These patients have often been through several "re-do" coronary bypass procedures and multiple percutaneous coronary interventions.

Surgical and interventional options for these patients typically have been exhausted or will result in only partial revascularization. Therefore, therapy remains limited to the use of multiple anti-anginal medications, reduced activity, exertion, and stress level, and significant alteration and limitation of lifestyle.

The goal of this emerging approach is to therapeutically induce the growth and development of new vasculature in zones of severe ischemia in the myocardium, with the hope that new capillaries and arterioles generated will connect to remnant existing vasculature. These neovessels are viewed to act as collaterals, perfusing ischemic territories unapproachable by macro procedures such as PCI and/or CABG.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Refractory Angina Pectoris
Study Start Date : February 2008
Estimated Primary Completion Date : August 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Angina Shock

Arm Intervention/treatment
Active Comparator: 2 Drug: Anti-hypertensive drugs
ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.

Experimental: 1 Procedure: Extra-corporeal shockwave
Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.

Primary Outcome Measures :
  1. Alleviation of anginal symptoms [ Time Frame: 06 months ]

Secondary Outcome Measures :
  1. The change in SPECT in perfusion from baseline to 6 months post-baseline (17 segments model [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female, 18 years or older.
  • Diagnosis of chronic stable angina pectoris. Diagnosis is based on medical history, complete physical evaluation, and Exercise Single-Photon Emission Computed Tomography (Exercise SPECT).
  • Patient has documented myocardial segments with reversible ischemia and or hibernation.
  • Patient is classified as AP CCS of III or IV.
  • Patient should be on a stable dosage of medication used to treat angina for at least 6 weeks prior to enrollment.
  • Patients demonstrates exercise tolerance time (ETT) duration <10 minutes on a modified Bruce protocol on 2 consecutive tests (tests no less than 24 hours and no more than 2 weeks apart), with the second test within 25% of the first (Patients should not be informed of exercise restrictions required for entry into the study).
  • Patient has refused to undergo another angioplasty or CABG.
  • Patient has signed an informed consent form.
  • Patient's condition should be stable and should have a life expectancy of >12 months.
  • Patient's current and past medical condition and status will be assessed using previous medical history, physical evaluation, and the physicians (principle investigator's) medical opinion.
  • Newly diagnosed type II diabetes.

Exclusion Criteria:

  • Chronic lung disease including emphysema and pulmonary fibrosis.
  • Active endocarditis, myocarditis or pericarditis.
  • Patient is simultaneously participating in another device or drug study, or has participated in any
  • Clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization, or any ESWT machine for neovascularization of a competitor company within 3 months of entry into the study.
  • Patients who are unwilling or unable to cooperate with study procedure.
  • Patients who are unwilling to quit smoking during the study procedure (including screening phase)
  • Patients who had myocardial infarction (MI) less than 3 months prior to treatment.
  • Patients who are diagnosed with a 3rd and 4th degree heart valve disease.
  • Patient with intraventricular thrombus.
  • Pregnancy.
  • Patient with a malignancy in the area of treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00776568

Layout table for location information
Karachi Institute of Heart Diseases
Karachi, Pakistan
Sponsors and Collaborators
Universal Research Group
Layout table for investigator information
Principal Investigator: Prof. Abdul Samad, MD Karachi Institute of Heart Diseases
Additional Information:
Layout table for additonal information
Responsible Party: Executive Director, Karachi Institute of Heart Diseases Identifier: NCT00776568    
Other Study ID Numbers: URG/UQ/002/01
First Posted: October 21, 2008    Key Record Dates
Last Update Posted: October 21, 2008
Last Verified: October 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Angina Pectoris
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Neurologic Manifestations
Antihypertensive Agents